 |
PDBsum entry 3fqq
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Metal binding protein
|
PDB id
|
|
|
|
3fqq
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.48
- RNA-directed Rna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
RNA(n)
|
+
|
ribonucleoside 5'-triphosphate
|
=
|
RNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.4.21.98
- hepacivirin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.3.4.22.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.6.1.15
- nucleoside-triphosphate phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a ribonucleoside 5'-triphosphate + H2O = a ribonucleoside 5'-diphosphate + phosphate + H+
|
 |
 |
 |
 |
 |
ribonucleoside 5'-triphosphate
|
+
|
H2O
|
=
|
ribonucleoside 5'-diphosphate
|
+
|
phosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.6.4.13
- Rna helicase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O = ADP + phosphate + H+
|
 |
 |
 |
 |
 |
ATP
|
+
|
H2O
|
=
|
ADP
|
+
|
phosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Virol
83:4395-4403
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus.
|
|
R.A.Love,
O.Brodsky,
M.J.Hickey,
P.A.Wells,
C.N.Cronin.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
A new protein expression vector design utilizing an N-terminal six-histidine tag
and tobacco etch virus protease cleavage site upstream of the hepatitis C virus
NS5A sequence has resulted in a more straightforward purification method and
improved yields of purified NS5A domain I protein. High-resolution diffracting
crystals of NS5A domain I (amino acids 33 to 202) [NS5A(33-202)] were obtained
by using detergent additive crystallization screens, leading to the structure of
a homodimer which is organized differently from that published previously (T. L.
Tellinghuisen, J. Marcotrigiano, and C. M. Rice, Nature 435:374-379, 2005) yet
is consistent with a membrane association model for NS5A. The monomer-monomer
interface of NS5A(33-202) features an extensive buried surface area involving
the most-highly conserved face of each monomer. The two alternate structural
forms of domain I now available may be indicative of the multiple roles emerging
for NS5A in viral RNA replication and viral particle assembly.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
T.Asselah
(2011).
NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C.
|
| |
J Hepatol,
54,
1069-1072.
|
 |
|
|
|
|
 |
A.Nordle Gilliver,
S.Griffin,
and
M.Harris
(2010).
Identification of a novel phosphorylation site in hepatitis C virus NS5A.
|
| |
J Gen Virol,
91,
2428-2432.
|
 |
|
|
|
|
 |
C.L.Murray,
and
C.M.Rice
(2010).
Hepatitis C: An unsuspected drug target.
|
| |
Nature,
465,
42-44.
|
 |
|
|
|
|
 |
F.Fernandes,
I.U.Ansari,
and
R.Striker
(2010).
cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.
|
| |
PLoS One,
5,
e9815.
|
 |
|
|
|
|
 |
J.A.Lemm,
D.O'Boyle,
M.Liu,
P.T.Nower,
R.Colonno,
M.S.Deshpande,
L.B.Snyder,
S.W.Martin,
D.R.St Laurent,
M.H.Serrano-Wu,
J.L.Romine,
N.A.Meanwell,
and
M.Gao
(2010).
Identification of hepatitis C virus NS5A inhibitors.
|
| |
J Virol,
84,
482-491.
|
 |
|
|
|
|
 |
M.Gao,
R.E.Nettles,
M.Belema,
L.B.Snyder,
V.N.Nguyen,
R.A.Fridell,
M.H.Serrano-Wu,
D.R.Langley,
J.H.Sun,
D.R.O'Boyle,
J.A.Lemm,
C.Wang,
J.O.Knipe,
C.Chien,
R.J.Colonno,
D.M.Grasela,
N.A.Meanwell,
and
L.G.Hamann
(2010).
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
|
| |
Nature,
465,
96.
|
 |
|
|
|
|
 |
R.A.Fridell,
D.Qiu,
C.Wang,
L.Valera,
and
M.Gao
(2010).
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
|
| |
Antimicrob Agents Chemother,
54,
3641-3650.
|
 |
|
|
|
|
 |
T.L.Foster,
T.Belyaeva,
N.J.Stonehouse,
A.R.Pearson,
and
M.Harris
(2010).
All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding.
|
| |
J Virol,
84,
9267-9277.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |